Background: Although obesity was an independent risk factor for fertility-sparing treatment in endometrial atypical hyperplasia (EAH) and endometrioid endometrial cancer (EEC), the roles of other weight statuses and related metabolism were unclear. This study aimed to investigate the body mass index (BMI) interval that produced optimal treatment efficacy and the effects of related metabolic disorders in EAH/EEC patients.
Methods: A total of 286 patients (including 209 EAH and 77 well-differentiated EEC) under progestin therapy were retrospectively analyzed. The cumulative complete response (CR) rate, relapse rate, and fertility outcomes were compared among different weight or metabolic statuses.
Results: Underweight and overweight/obese status significantly decreased the cumulative 16-week and 32-week CR rate ( = 0.004, = 0.022, respectively). The highest 16-week CR rate was observed at a BMI of 21-22 kg/m in the overall population ( = 0.033). Obesity (HR 0.37, 95%CI 0.15-0.90, = 0.029) and PCOS (HR 0.55, 95%CI 0.31-0.99, = 0.047) were associated with lower 16-week CR rate. Hyperuricemia (HR 0.66, 95%CI 0.45-0.99, = 0.043) was associated with lower 32-week CR rate. The 16-week and 32-week CR rate ( = 0.036, = 0.008, respectively) were significantly lower in patients exhibiting both obesity and hyperuricemia.
Conclusions: The optimal fertility-sparing treatment efficacy was observed at a BMI of 21-22 kg/m in EAH/EEC. Hyperuricemia was an independent risk factor for long-term treatment outcomes.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9599415 | PMC |
| http://dx.doi.org/10.3390/cancers14205024 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Coexisting growing teratoma syndrome and gliomatosis peritonei following ovarian immature teratoma: a case report and literature review.
Turk J Med Sci
December 2024
Department of Obstetrics and Gynecology, Faculty of Medicine, University of Health Sciences, Ankara, Turkiye.
Growing teratoma syndrome (GTS) is characterized by a reduction in serum tumor markers despite the growth of a benign mature teratomatous mass following chemotherapy for germ cell tumors. Gliomatosis peritonei (GP) typically accompanies ovarian teratomas, marked by the dissemination of mature glial tissue across the peritoneum. The concurrent presence of GTS and GP after treatment for ovarian immature teratoma (IMT) is notably rare, with approximately 20 reported cases.
View Article and Find Full Text PDFCase report: A successful live birth after fertilization and embryo transfer in a patient with endometrial cancer who was treated conservatively.
Front Oncol
December 2024
Department of Obstetrics and Gynecology, School of Medicine, Nankai University, Tianjin, China.
Objective: To describe a patient conceiving with fertilization and embryo transfer(IVF-ET) after conservative treatment of early stage endometrial cancer.
Patient: A 31-year-old multiparous woman diagnosed with highly-differentiated (G1) endometrial adenocarcinoma (grade IA).
Interventions: After four courses of conservative treatment each followed by hysteroscopic biopsy and endometrial curettage,assisted reproductive technology was performed.
A giant ovarian atypical proliferative mucinous tumor in a young adult: A rare case report and review of the literature.
Int J Surg Case Rep
December 2024
Faculty of Medicine, Kilimanjaro Christian Medical University College, Moshi, Tanzania; Department of Pathology, Kilimanjaro Christian Medical Centre, Moshi, Tanzania; Kilimanjaro Clinical Research Institute, Moshi, Tanzania. Electronic address:
Introduction And Importance: Ovarian atypical proliferative mucinous tumor (APMT) is a low-malignant or borderline tumor that originates from the ovary's surface epithelium. This tumor can grow to a massive size, causing abdominal distention, which can result in a variety of compression symptoms if it is not discovered early.
Case Presentation: A 23-year-old female presented with a chronic, gradually developing abdominal distention that had been persistent for a year.
Malignant struma ovarii in pregnancy: A case report.
Gynecol Oncol Rep
December 2024
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, McMaster University, 699 Concession Street, Hamilton, Ontario L8V 5C2, Canada.
Article Synopsis
- * A 27-year-old pregnant patient was diagnosed with malignant struma ovarii after emergency surgery for ovarian torsion revealed a 3 cm tumor, initially monitored during pregnancy due to the lack of high-risk features.
- * After giving birth, the patient had a recurrence treated with extensive surgeries and radioactive iodine therapy, and she remained disease-free three years post-diagnosis, highlighting the need for personalized treatment approaches for MSO.
[Megestrol acetate plus metformin for fertility-sparing treatment of atypical endometrial hyperplasia and early-stage endometrial adenocarcinoma: a prospective study].
Nan Fang Yi Ke Da Xue Xue Bao
November 2024
Department of Gynecology, First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China.
Article Synopsis
- The study aimed to assess the effectiveness of combining medroxyprogesterone acetate (MA) and metformin as a fertility-sparing treatment for atypical endometrial hyperplasia (AEH) and early-stage endometrial adenocarcinoma (G1 EAC).
- It involved 60 patients who were divided into two groups, one receiving only MA and the other receiving MA plus metformin, with both treatments monitored for up to 12 months through regular follow-ups.
- Results showed similar complete response rates for both treatments, but the combined group had no significant weight gain compared to the group taking MA alone, and it led to favorable changes in certain endometrial biomarkers.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!